Ignite Creation Date:
2025-12-26 @ 10:32 AM
Ignite Modification Date:
2025-12-29 @ 12:18 PM
Study NCT ID:
NCT00390728
Status:
COMPLETED
Last Update Posted:
2010-08-31
First Post:
2006-10-18
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Insulin Glargine in Type I Diabetes Mellitus> Main Study "AT.LANTUS": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-study: "HALT"(Hypoglycaemia Avoidance With Lantus Trial)
Sponsor:
Sanofi
Organization:
Study Overview
Official Title:
A Phase IIIb/IV, Multinational, Multicentre, Randomised, Open Study to Establish the Optimal Method for Initiating and Maintaining Lantus® (Insulin Glargine) Therapy Based on a Comparison of Two Treatment Algorithms to Determine Optimal Metabolic Outcomes, Safety, and Satisfaction in Subjects With Type 1 Diabetes Mellitus/ "HALT" Sub-study: Multicentre, Open Clinical Trial to Assess the Effect of Insulin Glargine on Symptomatic Hypoglycaemia, Fear of Hypoglycaemia and Quality of Life in Patients With Type 1 Diabetes
Status:
COMPLETED
Status Verified Date:
2010-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AT-LANTUS
Brief Summary:
Primary objective:
AT.LANTUS main study\*
* To determine the optimal treatment algorithm for insulin glargine based on the incidence of severe hypoglycaemia.(\*Target Number of patients for the main study:2346)
HALT Sub-study\*\*
* To test the hypothesis that titration regimens involving insulin glargine are associated with changes in the rate of symptomatic hypoglycaemic episodes together with changes in Fear of Hypoglycaemia as measured by the HFS-98 Questionnaire in Type I diabetes.(\*\*Target Number of patients for the Sub-study: 250)
Secondary objectives:
AT.LANTUS main study
To determine:
* the incidence of symptomatic, asymptomatic and nocturnal hypoglycaemia with each treatment regimen
* the difference in glycemic control as measured by HbA1c and fasting blood glucose with each treatment regimen
* the difference in glycemic control as measured by HbA1c and fasting blood glucose between baseline and end of treatment
* the safety on the use of insulin glargine in each treatment algorithm
* the change in subject weight with each treatment regimen
* the change in insulin doses with each treatment regimen
* the change in Diabetes Treatment Satisfaction (Diabetes Treatment Satisfaction Questionnaire, sub-study only) with each treatment regimen
HALT Sub-study (baseline to study end)
* To estimate the relationship between change in HbA1c and incidence of hypoglycaemia
* To examine the effect of insulin glargine on Quality of Life (EQ-5D) in relation to incidence of hypoglycaemia
* To examine the effect of insulin glargine on the Hospital Anxiety and Depression Scale (HADS) in relation to the incidence of hypoglycaemia
* To examine the use of the Prescription Plan versus standard management (no Prescription Plan)
AT.LANTUS main study\*
* To determine the optimal treatment algorithm for insulin glargine based on the incidence of severe hypoglycaemia.(\*Target Number of patients for the main study:2346)
HALT Sub-study\*\*
* To test the hypothesis that titration regimens involving insulin glargine are associated with changes in the rate of symptomatic hypoglycaemic episodes together with changes in Fear of Hypoglycaemia as measured by the HFS-98 Questionnaire in Type I diabetes.(\*\*Target Number of patients for the Sub-study: 250)
Secondary objectives:
AT.LANTUS main study
To determine:
* the incidence of symptomatic, asymptomatic and nocturnal hypoglycaemia with each treatment regimen
* the difference in glycemic control as measured by HbA1c and fasting blood glucose with each treatment regimen
* the difference in glycemic control as measured by HbA1c and fasting blood glucose between baseline and end of treatment
* the safety on the use of insulin glargine in each treatment algorithm
* the change in subject weight with each treatment regimen
* the change in insulin doses with each treatment regimen
* the change in Diabetes Treatment Satisfaction (Diabetes Treatment Satisfaction Questionnaire, sub-study only) with each treatment regimen
HALT Sub-study (baseline to study end)
* To estimate the relationship between change in HbA1c and incidence of hypoglycaemia
* To examine the effect of insulin glargine on Quality of Life (EQ-5D) in relation to incidence of hypoglycaemia
* To examine the effect of insulin glargine on the Hospital Anxiety and Depression Scale (HADS) in relation to the incidence of hypoglycaemia
* To examine the use of the Prescription Plan versus standard management (no Prescription Plan)
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: